5AR1 Stock Overview
Operates a next generation blockchain platform. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
ALT5 Sigma Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.08 |
52 Week High | US$5.20 |
52 Week Low | US$0.31 |
Beta | 2.15 |
11 Month Change | -16.80% |
3 Month Change | -1.89% |
1 Year Change | 541.98% |
33 Year Change | -53.36% |
5 Year Change | -35.00% |
Change since IPO | -92.28% |
Recent News & Updates
Recent updates
Shareholder Returns
5AR1 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 4.5% | -1.0% | 0.2% |
1Y | 542.0% | -19.3% | 8.5% |
Return vs Industry: 5AR1 exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: 5AR1 exceeded the German Market which returned 8.5% over the past year.
Price Volatility
5AR1 volatility | |
---|---|
5AR1 Average Weekly Movement | 13.6% |
Pharmaceuticals Industry Average Movement | 6.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.9% |
10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 5AR1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5AR1's weekly volatility has decreased from 24% to 14% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1976 | 5 | Peter Tassiopoulos | alt5sigma.com |
ALT5 Sigma Corporation operates a next generation blockchain platform. It engages in the tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. The company’s products include ALT 5 Prime, an electronic over-the-counter trading platform to buy and sell digital assets; and ALT 5 Pay that enables payment processors to accept digital assets as payments, as well as make payment in digital assets.
ALT5 Sigma Corporation Fundamentals Summary
5AR1 fundamental statistics | |
---|---|
Market cap | €29.25m |
Earnings (TTM) | -€17.77m |
Revenue (TTM) | €6.77m |
4.2x
P/S Ratio-1.6x
P/E RatioIs 5AR1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
5AR1 income statement (TTM) | |
---|---|
Revenue | US$7.11m |
Cost of Revenue | US$3.65m |
Gross Profit | US$3.46m |
Other Expenses | US$22.11m |
Earnings | -US$18.65m |
Last Reported Earnings
Sep 28, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.33 |
Gross Margin | 48.65% |
Net Profit Margin | -262.26% |
Debt/Equity Ratio | 46.4% |
How did 5AR1 perform over the long term?
See historical performance and comparison